Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Daiichi Sankyo Co Ltd And Ranbaxy Laboratories Ltd Announce Intention To Integrate Business Operations In Thailand


Tuesday, 15 Jan 2013 10:05pm EST 

Daiichi Sankyo Co Ltd and Ranbaxy Laboratories Ltd announced their intention to integrate their business operations in Thailand, to leverage and maximize the synergies of the Hybrid Business Model, which is expected to commence business on April 1, 2013. Under this strategy, Daiichi Sankyo and Ranbaxy would integrate the management of Daiichi Sankyo's Thailand subsidiary, Daiichi Sankyo (Thailand) Ltd. (DSTH) and Ranbaxy's Thailand subsidiary, Ranbaxy Unichem Co., Ltd. (RUCL). the new representative of the proposed integrated entity will be, head Suthas Thongprasert, who presently heads DSTH. 

Company Quote

1689.5
21.0 +1.26%
1:00am EST